ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,529.50
3.50 (0.23%)
28 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.50 0.23% 1,529.50 1,531.50 1,532.00 1,541.50 1,523.00 1,537.00 8,077,646 16:35:26
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 12.79 63.05B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,526p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,820.00p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £63.05 billion. Gsk has a price to earnings ratio (PE ratio) of 12.79.

Gsk Share Discussion Threads

Showing 19851 to 19874 of 33350 messages
Chat Pages: Latest  806  805  804  803  802  801  800  799  798  797  796  795  Older
DateSubjectAuthorDiscuss
29/7/2019
14:41
Well, cable, the culprit in this plot, could go lower.
sogoesit
29/7/2019
14:38
Out at 1731 hopefully made the right call for one. Burnt out with VOD and a few others before in terms of timing.
letsmakesome
29/7/2019
13:54
Yes TM you and me are in the same boat.
abdullla
29/7/2019
13:49
abdullla, you are absolutely right. But for the record I made a big profit with VOD and took out all of my capital well ahead of the sale of the Verizon stake, shifting into GSK. Just look at Vodafone now - no presence in the USA, more a broadband cable and network service provider (notwithstanding a Mast company!), with little ambition to maintain a global leadership in cell phones and services. An appalling build up of debt, such that they axed the dividend.

The company destroyed its business model for the worse, therefore I would no longer choose to invest in it.

GSK appears to be better managed and better controlled and developing a more logical approach to improving its model, but the uncertainty is mine in so far as I find it hard to determine the future value of its potentially devolved businesses.

tradermichael
29/7/2019
13:13
Usually inadviseable to bet against momentum but difficult to say whether this has enough to continue and break the 10 year "consolidation" (going nowhere) pattern.

My long play is founded on the separation. I have a similar play with Reckitt Benckiser's potential separation; again with a new CEO coming along (and which also made me money with Indivior).
Separation usually implies that the sum of the parts will be greater than the whole.
We shall see but in any case collect 5%+ every year.

sogoesit
29/7/2019
13:09
Maybe it reminds TM of the bitter old memories of Vodafone's split with VZW,ouch what a disaster that was.
abdullla
29/7/2019
11:47
Yes, I will say that 1600 is the new 1500, but trading down at that level may take time especially with the next xd coming up on 8 Aug. The share really seems to have a head of steam this month, so it could be that I'll pass on the 19p this time around because it may not be an easy re-entry.


Nevertheless, I still have some (£182K) that have been sitting at 1732p for a long time earning good dividends, so I'm happy either way!


Unlike you, Nik, I really don't want to be in when the split takes place as I find it gets a little messy working out what the perceived market value of the two companies will be, and I prefer to let the market settle.

Good luck! ……. ;0)

tradermichael
29/7/2019
11:25
Well done TM. You, like me, have used the 1600 down to 1500 ploy recently. Are we resetting this to 1700 down to 1600? Personally, I am going to hold for a while longer as I haven't worked out where this is going as yet. Also I want to be in when the separation occurs. GLA. N.R.
nik rosa
29/7/2019
10:46
OUT - 8579 shares @ 1712.00 …… ;0)
tradermichael
29/7/2019
10:20
A lot of further coverage in the FT about M&A in the pharma sector continuing apace.

Latest is merger of Pfizer and Mylan for off-patent drugs businesses.


Looks like Pfizer and Glaxo are both exiting several businesses, stream-lining/slimming down and both concentrating on news drugs including oncology.

FT speculates that pharma sector M&A is set to continue for some time to come.


ALL IMO. DYOR.
QP

quepassa
29/7/2019
09:03
Hopefully it's the latter :)
letsmakesome
29/7/2019
08:18
“Sellwell̶1; and other shorts appear to have jumped the gun so far but will the 1700/1710 area be top of the range or could momentum lead to a break through?
sogoesit
26/7/2019
15:13
Long term chart and current state of markets

My call is 1150p by this coming xmas

dyor

buywell2
26/7/2019
14:12
Been a nice week for the longs.
Here's wishing us good luck for the short term to 1710 in the next week or so.

(PS: TraderMichael, I thought some EU country yields are negative now? Austria and someone had a 100-year at close to zero recently. This environment is hsitorically abnormal and, imv, artificial but will probably continue for a few years more.)

sogoesit
26/7/2019
09:10
£1 = US$1.24
tradermichael
26/7/2019
08:00
The European Central Bank has opened the door to a further interest rate cut as well as additional stimulus measures as global trade tensions threaten the continent's economic outlook.
It comes as the bloc struggles with a manufacturing recession particularly afflicting Germany, its largest economy.
Rates are already at or around zero but in its latest monetary policy announcement the ECB raised the possibility that they could be cut further in the first half of 2020, giving up a previous pledge that they would remain unchanged.

tradermichael
25/7/2019
09:09
The Lex Column in today's FT speculates that, with the disposal of the consumer division to Pfizer and subsequent reduction in size of the Group, that GSK may become an attractive target for another larger pharma company.

See full FT article for context, headed: "GSK. betting the pharma".


ALL IMO. DYOR.
QP

quepassa
24/7/2019
23:58
Cheaper rivals eat into Glaxo's profits but vaccine sales rise as drug giant ramps up spending on R&D

++ Glaxo has been hit by generic competition to its Advair inhalers in America
++ It expects earnings to fall by 3 per cent-5 per cent this year
++ Shingrix vaccine sales more than doubled in the second quarter

philanderer
24/7/2019
22:22
Wow what a range !
tim 3
24/7/2019
15:07
Looks solid enough particularly in the light of a weak market on both sides of the pond.
patientcapital
24/7/2019
14:41
Glaxo (GSK) Beats Earnings & Revenue Estimates in Q2
philanderer
24/7/2019
13:51
what about the porsche driver,oh dear...
lippy4
24/7/2019
13:45
Unless you are Montyplonker the no. 1 trader who sold 2 days ago so he could "rebuy at 1600 or less"

Meanwhile I have hung onto all mine...

lurker
24/7/2019
13:31
Unless you're lucky, as my old dad used to say. buy and hold is the thing with a share like this, collect the dividends and keep trading costs to a minimum.
lindowcross
Chat Pages: Latest  806  805  804  803  802  801  800  799  798  797  796  795  Older